


# AffloVest<sup>®</sup> HFCWO THERAPY FOR "AT-RISK" RESPIRATORY PATIENTS

COPD and Bronchiectasis patients using AffloVest high frequency chest wall oscillation (HFCWO) therapy have shown reduced hospitalizations for respiratory causes and better overall respiratory health.<sup>1</sup>

## PRE VS POST AFFLOVEST HFCWO THERAPY<sup>1</sup>



- 96.2 % reduction in hospitalizations<sup>1</sup>
- 82.4% reduction in emergency visits<sup>1</sup>
- 87.3% reduction in antibiotic usage<sup>1</sup>

### AffloVest is the first fully mobile during use HFCWO airway clearance therapy

- Engineered to anatomically target all 5 lobes of the lungs, posteriorly and anteriorly
- Eight oscillating motors loosen, thin and mobilize lung secretions
- Three modes of oscillation treatment, three adjustable intensity levels for custom treatments



Now is the time to promote pulmonary and bronchial hygiene for at-risk pulmonary patients to be in the best health possible with AffloVest

For more information, visit [afflovest.com](https://afflovest.com)

AffloVest requires a doctor's prescription for treatment by High Frequency Chest Wall Oscillation (HFCWO). The AffloVest has received the FDA's 510k clearance for U.S. market availability, and is approved for Medicare, Medicaid, and private health insurance reimbursement under the Healthcare Common Procedure Coding System (HCPCS) code E0483 – High Frequency Chest Wall Oscillation. The AffloVest is also available through the U.S Department of Veterans Affairs/Tricare. Patients must qualify to meet insurance eligibility requirements.

1. Foley, B. et al. Reduction in Antibiotic Use, Emergency Visits and Hospitalizations in COPD and Bronchiectasis Patients after Initiating AffloVest HFCWO Therapy. RT Magazine. January/February 2021.